Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across cancer, cardiovascular disease and inflammation

          Learn more

        • Cancer
        • Inflammation
        • Cardiovascular
        • Programs
        • Laboratories
        • Diseases
        • Expertises
        • Services and instrumentation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your will
        • Donate in Memory
  • Impact
        • Impact

          Our research develops new diagnostics, treatments and cures for some of the most deadly and debilitating diseases affecting society today

          Learn more

        • Breakthroughs
        • Community and research
  • Careers & studies
        • Careers & Studies

          Take the next step in your career with Centenary, Australia’s foremost clinically integrated medical research institute

          Learn more

        • Career opportunities
        • Life at Centenary
        • Post-Doctorate Research
        • PhD
        • Masters
        • Honours
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events

        • News
        • Events
        • Media Hub
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Our researchers
        • Contact
  • Donate
    Centenary Institute > News > New discovery may hold key to fighting deadly infections

New discovery may hold key to fighting deadly infections

Date time 12 May, 2022
News Type News type Media release
Centenary Institute research has revealed new insight into tackling mycobacterial infections which are responsible for chronic diseases that include tuberculosis (TB), leprosy and serious skin ulcerations.

Reported in the peer reviewed journal, Life Science Alliance, the research found a new way to improve host immunity by decreasing potassium levels in immune cells. Significantly, this could offer up an entirely new approach to fighting infectious diseases.

“Mycobacterial infections are caused by bacteria from the Mycobacteriaceae family,” said lead author of the study, Dr Elinor Hortle from the Centenary Institute.

“They cause significant harm and mortality to human health. With an estimated one quarter of the world’s population infected with TB, new approaches to overcoming mycobacterial infections and preventing disease are desperately needed.”

In the study, the researchers used zebrafish and human cells to explore the role of inflammasomes in fighting mycobacteria infection. Multi-protein complexes that exist inside of cells, inflammasomes, are a key part of the innate immune system. They induce inflammation to fight harmful bacteria and infection.

“Many successful pathogens, including mycobacteria, have evolved strategies to limit inflammasomes from activating, to escape the body’s immune response,” Dr Hortle said.

“We wanted to see if we could aid inflammasome activation in response to mycobacteria exposure. Boosting the immune system in this way could help in the fight against chronic bacterial diseases.”

Central to the study was potassium efflux – a process necessary for inflammasome activation to occur. It is where potassium crosses the cell membrane in response to mycobacteria or other pathogenic activity. A corresponding drop of potassium levels inside the cell triggers inflammasome activation.

Critically, the researchers found that mycobacterial infection increased levels of the enzyme OXSR1 (Oxidative Stress Responsive Kinase 1) which causes cells to hoard intracellular potassium. Inhibiting OXSR1 decreased intracellular potassium levels which in turn improved inflammasome activation and reduced mycobacterial count.

“Our findings that OXSR1 can be targeted to decrease bacterial burden defines a new avenue for therapeutic development,” said Dr Stefan Oehlers, study senior author and researcher affiliated with both the Centenary Institute and A*STAR Infectious Diseases Labs (Singapore).

“It shows that potassium pathways in the cell can be influenced by new therapeutic drugs to activate inflammasomes, to control mycobacterial infections.”

Dr Oehlers said that given mycobacteria are not the only pathogens which affect inflammasome activation, OXSR1 inhibition may be an effective therapy with broad applicability across other disease areas.

Themes

  • Inflammation

    Inflammation

People

  • Dr Elinor Hortle

    Postdoctoral Research Fellow

Media enquires

For all media and interview enquiries, please contact Tony Crawshaw, Media and Communications Manager

Phone number Phone Number 0402 770 403

Email Email t.crawshaw@centenary.org.au

Media Release

New discovery may hold key to fighting deadly infections

Download

Recent Stories

  • 2GB Healthy Living program interviews Dr Elinor Hortle

    Dr Elinor Hortle, medical researcher at the Centenary Institute has been interviewed on Sydney radio 2GB’s Healthy Living program, discussing her latest findings on tackling mycobacterial infections. Responsible for diseases that include tuberculosis (TB), leprosy and serious skin ulcerations, mycobacterial infections cause significant harm and mortality to human health. Approximately 1.5 million people die each ...
    News Type: Media coverage
    Date 18 May 2022
  • World-first study reveals why people with COPD are more susceptible to COVID-19

    Researchers from the Centenary Institute and the University of Technology Sydney have published the first study showing why people with chronic obstructive pulmonary disease (COPD) are at higher risk of developing severe COVID-19. The findings, reported in the American Journal of Respiratory and Critical Care Medicine,could lead to the development of new therapeutic interventions that ...
    News Type: Media release
    Date 17 May 2022
  • Research Australia’s ‘Inspire Magazine’ features Professor Chris Semsarian AM

    Professor Chris Semsarian AM, Head of the Centenary Institute’s Agnes Ginges Centre for Molecular Cardiology, has featured in an article in Research Australia’s Inspire Magazine outlining the importance of philanthropy to medical research. The article highlights how the philanthropic support of Mrs Agnes Ginges and her husband, the late Mr Berel Ginges (facilitated by eminent ...
    News Type: Media coverage
    Date 03 May 2022
  • Early detection of lung cancer to be investigated

    Dr Annalicia Vaughan from the Centenary UTS Centre for Inflammation is the successful recipient of the Kenyon Foundation Inflammation Award for 2022. The Award, valued at $20,000, will support Dr Vaughan’s study into identifying new microbial-derived biomarkers for the early diagnosis and treatment of lung cancer. The leading cause of cancer death, lung cancer is ...
    News Type: Media release
    Date 05 Apr 2022

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About
  • Governance
  • Corporate information

Research

  • Programs
  • Laboratories
  • Our researchers
  • News
  • Media hub

Careers & studies

  • Career opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram